journal article·2021-01

An Ultrahigh‐Field‐Tailored T1–T2 Dual‐Mode MRI Contrast Agent for High‐Performance Vascular Imaging

Jin Wang, Yinhang Jia, Qiyue Wang, Zeyu Liang, Guangxu Han, Zejun Wang, Jiyoung Lee, Meng Zhao, Fangyuan Li, Ruiliang Bai, Daishun Ling

Advanced Materials· Volume 33· Issue 2
Publisher page

Abstract

Abstract The assessment of vascular anatomy and functions using magnetic resonance imaging (MRI) is critical for medical diagnosis, whereas the commonly used low‐field MRI system (≤3 T) suffers from low spatial resolution. Ultrahigh field (UHF) MRI (≥7 T), with significantly improved resolution and signal‐to‐noise ratio, shows great potential to provide high‐resolution vasculature images. However, practical applications of UHF MRI technology for vascular imaging are currently limited by the low sensitivity and accuracy of single‐mode (T1 or T2) contrast agents. Herein, a UHF‐tailored T1–T2 dual‐mode iron oxide nanoparticle‐based contrast agent (UDIOC) with extremely small core size and ultracompact hydrophilic surface modification, exhibiting dually enhanced T1–T2 contrast effect under the 7 T magnetic field, is reported. The UDIOC enables clear visualization of microvasculature as small as ≈140 µm in diameter under UHF MRI, extending the detection limit of the 7 T MR angiography. Moreover, by virtue of high‐resolution UHF MRI and a simple double‐checking process, UDIOC‐based dual‐mode dynamic contrast‐enhanced MRI is successfully applied to detect tumor vascular permeability with extremely high sensitivity and accuracy, providing a novel paradigm for the precise medical diagnosis of vascular‐related diseases.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Lanthanide and Transition Metal Complexes · Nanoparticle-Based Drug Delivery · Characterization and Applications of Magnetic Nanoparticles

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Pharmaceutics College of Pharmaceutical Sciences Zhejiang University Hangzhou 310058 P. R. China

Interdisciplinary Institute of Neuroscience and Technology School of Medicine Zhejiang University Hangzhou 310029 P. R. China

Hangzhou Institute of Innovative Medicine College of Pharmaceutical Sciences Zhejiang University Hangzhou 310058 P. R. China

Key Laboratory of Biomedical Engineering of the Ministry of Education College of Biomedical Engineering & Instrument Science Zhejiang University Hangzhou 310027 P. R. China

Department of Physical Medicine and Rehabilitation of The Affiliated Sir Run Run Shaw Hospital Zhejiang University Hangzhou 310029 P. R. China

Funding

National Basic Research Program of China · National Natural Science Foundation of China · National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology · Natural Science Foundation of Zhejiang Province · Fundamental Research Funds for the Central Universities

References (51)

Show source-provided references
1. 10.1126/scitranslmed.300510110.1126/scitranslmed.3005101 ↗
2. 10.1038/s41551-020-0527-810.1038/s41551-020-0527-8 ↗
3. 10.1038/nm.328910.1038/nm.3289 ↗
4. 10.1126/scitranslmed.aaw895410.1126/scitranslmed.aaw8954 ↗
5. 10.1038/s41569-019-0305-z10.1038/s41569-019-0305-z ↗
6. 10.1038/nrclinonc.2014.12610.1038/nrclinonc.2014.126 ↗
7. 10.1016/j.addr.2017.08.00410.1016/j.addr.2017.08.004 ↗
8. 10.1016/j.biomaterials.2016.05.00210.1016/j.biomaterials.2016.05.002 ↗
9. 10.1038/nrclinonc.2012.210.1038/nrclinonc.2012.2 ↗
10. 10.1093/jnci/djj07010.1093/jnci/djj070 ↗
11. 10.1021/acs.chemrev.8b0036310.1021/acs.chemrev.8b00363 ↗
12. 10.1186/s40824-018-0130-110.1186/s40824-018-0130-1 ↗
13. 10.1021/acsnano.7b0772010.1021/acsnano.7b07720 ↗
14. 10.1021/acsnano.6b0795910.1021/acsnano.6b07959 ↗
15. 10.1002/adma.20147015710.1002/adma.201470157 ↗
16. 10.1097/RLI.000000000000028010.1097/RLI.0000000000000280 ↗
17. 10.1146/annurev-med-063014-12493610.1146/annurev-med-063014-124936 ↗
18. 10.1021/acsnano.9b0151110.1021/acsnano.9b01511 ↗
19. 10.1021/acsnano.5b0578310.1021/acsnano.5b05783 ↗
20. 10.1021/acs.chemrev.5b0011210.1021/acs.chemrev.5b00112 ↗
21. 10.1002/adma.20170429010.1002/adma.201704290 ↗
22. 10.1038/asiamat.2010.610.1038/asiamat.2010.6 ↗
23. 10.1016/j.mattod.2019.06.00310.1016/j.mattod.2019.06.003 ↗
24. 10.1016/j.addr.2017.08.00410.1016/j.addr.2017.08.004 ↗
25. 10.1002/jmri.2469110.1002/jmri.24691 ↗
26. 10.1039/C8NR06812G10.1039/C8NR06812G ↗
27. 10.1038/s41551-017-0116-710.1038/s41551-017-0116-7 ↗
28. 10.1021/ja203340u10.1021/ja203340u ↗
29. 10.1021/nn304605510.1021/nn3046055 ↗
30. 10.1073/pnas.061082110410.1073/pnas.0610821104 ↗
31. 10.1038/d41586-018-07182-710.1038/d41586-018-07182-7 ↗
32. 10.1002/jmri.2457310.1002/jmri.24573 ↗
33. 10.1007/s12274-016-1008-y10.1007/s12274-016-1008-y ↗
34. 10.4155/fmc.09.17410.4155/fmc.09.174 ↗
35. 10.1002/wnan.3610.1002/wnan.36 ↗
36. 10.1097/01.rli.0000184756.66360.d310.1097/01.rli.0000184756.66360.d3 ↗
37. 10.1021/acsnano.7b0307510.1021/acsnano.7b03075 ↗
38. 10.1021/nn405977t10.1021/nn405977t ↗
39. 10.1021/ja104503g10.1021/ja104503g ↗
40. 10.1039/C1CS15248C10.1039/C1CS15248C ↗
41. 10.1039/C7CS00316A10.1039/C7CS00316A ↗
42. 10.7150/thno.2378910.7150/thno.23789 ↗
43. 10.1097/RLI.0b013e3181ee6a4910.1097/RLI.0b013e3181ee6a49 ↗
44. 10.1021/acsami.8b1559410.1021/acsami.8b15594 ↗
45. Jeon M. · Adv. Mater.
46. 10.1021/cr068445e10.1021/cr068445e ↗
47. 10.1021/acs.chemmater.6b0026410.1021/acs.chemmater.6b00264 ↗
48. 10.1016/j.neuroimage.2017.01.01910.1016/j.neuroimage.2017.01.019 ↗
49. 10.3390/pharmaceutics403044210.3390/pharmaceutics4030442 ↗
50. 10.1200/JCO.2002.07.08910.1200/JCO.2002.07.089 ↗
51. 10.1038/nrc.2017.5110.1038/nrc.2017.51 ↗